A standardized protocol and AI-supported diagnostic framework for rapid, bedside identification of chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. Developed to integrate with emergency medical systems and hospitals, this solution provides critical tools for frontline triage, enhanced personnel safety, and faster, targeted medical treatment during CBRNE incidents.
The CBRNE Point of Care Testing (POCT) and Bedside Rapid Identification Protocol is a specialized framework designed to equip emergency medical services, hospitals, and medical hubs with the capability to rapidly detect and identify chemical, biological, radiological, nuclear, and explosive (CBRNE) agents. By moving diagnostic capabilities directly to the patient's bedside, this solution enables faster triage, improved safety for medical personnel, and the immediate application of targeted medical countermeasures. It addresses a critical gap in emergency response systems, replacing traditional, slower identification methods with modern, integrated clinical protocols.
The protocol comprises several key components developed through extensive simulation and research:
The solution is at TRL 7-8. It has been validated through rigorous research, including 21 simulations and 7 special tests conducted over a three-year development period (2022-2026). The protocol has been implemented in training workshops for medical personnel, successfully demonstrating its operational viability in real-world scenarios. It is currently being transitioned from project-based development into practical application...
Jagiellonian University is a comprehensive public research university in Krakow with a broad academic profile and an integrated medical college connected to a major hospital system. Industry partners engage through co-located core facilities, prototyping and analytical labs, and contract research, with access to a nearby research and technology park and startup incubation. Health system integration supports clinical research and translation with access to patient cohorts and regulated environments. Research is supported by competitive national funding and European Union programs, enabling collaborations that scale across borders. A dedicated technology transfer office manages IP, licensing, and spinout formation and offers industry-friendly agreements to streamline engagement.